This small stock may have just won earnings season already surging 33% in a single day

Investing

A woman takes a selfie with a dog

Ezequiel Becerra | AFP | Getty Images

A company responsible for keeping pets healthy may have just won earnings season.

PetMed Express soared more than 30% on Monday after the online pet pharmacy said its quarterly profit topped Wall Street’s estimates. The company reported earnings of 33 cents per share, while analysts were expecting earnings per share of 26 cents, according to Refinitiv. PetMed has missed estimates the last three quarters.

Despite beating expectations, PetMed’s net income fell about 36% since the same period last year as PetMed was forced to lower prices in a competitive pet-loving environment.

“Sales were negatively impacted by increased online competition and aggressive pricing in the market that forced us to reduce prices,” said Menderes Akdag, PetMed chief executive officer, on the earnings call.

Monday’s rally in the stock erased PetMed’s entire 16% year-to-date decline, but Credit Suisse, one of the three firms to cover the stock, said the improvement in tainted by a 16.2% fall in new customers, as companies like Chewy and Vetsource gain traction.

“While PETS faces several challenges, with intensifying competitive dynamics, we admit 2Q marks a turnaround in PETS margin deterioration, a trend we expect to continue,” said Credit Suisse research analyst Erin Wright.

PetMed, which has a market value of about $392 million, also announced a quarterly dividend of 27 cents per share on PetMed’s common stock.

—with reporting from CNBC’s Michael Bloom.

Articles You May Like

Nordstrom to go private in $6.25 billion deal with founding family, Mexican retailer
Trump’s 25% tariff could be an existential threat to Canada’s recovering auto industry
CFPB takes aim at ‘bait-and-switch’ credit card rewards — consumers forfeit about $500 million worth each year
GOP Budget Squabble Puts The Older Americans Act At Risk
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea, expanding use in U.S.

Leave a Reply

Your email address will not be published. Required fields are marked *